Kodiak Sciences Stock Surges After Strong Phase 3 Eye Drug Results
Kodiak Sciences shares surged after Zenkuda hit its primary endpoint in the GLOW2 Phase 3 study for diabetic retinopathy.
Already have an account? Sign in.